Dietary iron restriction prevents further deterioration of renal damage in a chronic kidney disease rat model

Journal of Hypertension

Volumn 31, Issue 6, 2013, Pages 1203-1213

  Naito, Yoshiro ^a   Fujii, Aya ^a   Sawada, Hisashi ^a   Hirotani, Shinichi ^a   Iwasaku, Toshihiro ^a   Okuhara, Yoshitaka ^a   Eguchi, Akiyo ^a   Ohyanagi, Mitsumasa ^a   Tsujino, Takeshi ^a   Masuyama, Tohru ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

chronic kidney disease; hypertension; iron; mineralocorticoid receptor

Indexed keywords

IRON; MINERALOCORTICOID RECEPTOR; POTASSIUM; RAC1 PROTEIN; SODIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL PROTOCOL; CONTROLLED STUDY; DIET THERAPY; DISEASE ASSOCIATION; HYPERTENSION; IRON RESTRICTION; KIDNEY; KIDNEY INJURY; MALE; NEPHRECTOMY; NONHUMAN; POTASSIUM EXCRETION; POTASSIUM URINE LEVEL; PRIORITY JOURNAL; RAT; SODIUM URINE LEVEL; SURGICAL TECHNIQUE; THERAPY EFFECT; TREATMENT DURATION; URINALYSIS;

EID: 84877584908     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328360381d     Document Type: Article

References (23)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296-1305.
2. Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, Schneider KA. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 1989; 13 (5 Suppl):I80-I93.
3. Harris DC, Tay C, Nankivell BJ. Lysosomal iron accumulation and tubular damage in rat puromycin nephrosis and ageing. Clin Exp Pharmacol Physiol 1994; 21:73-81.
4. Izuhara Y, Nangaku M, Inagi R, Tominaga N, Aizawa T, Kurokawa K, et al. Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol 2005; 16:3631-3641.
5. Nankivell BJ, Boadle RA, Harris DC. Iron accumulation in human chronic renal disease. Am J Kidney Dis 1992; 20:580-584.
6. Nankivell BJ, Chen J, Boadle RA, Harris DC. The role of tubular iron accumulation in the remnant kidney. J Am Soc Nephrol 1994; 4:1598-1607.
7. Naito Y, Fujii A, Sawada H, Hirotani S, Iwasaku T, Eguchi A, et al. Effect of iron restriction on renal damage and mineralocorticoid receptor signaling in a rat model of chronic kidney disease. J Hypertens 2012; 30:2192-2201.
8. Bro S, Bentzon JF, Falk E, Andersen CB, Olgaard K, Nielsen LB. Chronic renal failure accelerates atherogenesis in apolipoprotein E-deficient mice. J Am Soc Nephrol 2003; 14:2466-2474.
9. Naito Y, Tsujino T, Fujimori Y, Sawada H, Akahori H, Hirotani S, et al. Impaired expression of duodenal iron transporters in Dahl salt-sensitive heart failure rats. J Hypertens 2011; 29:741-748.
10. Naito Y, Hirotani S, Sawada H, Akahori H, Tsujino T, Masuyama T. Dietary iron restriction prevents hypertensive cardiovascular remodeling in Dahl salt-sensitive rats. Hypertension 2011; 57:497-504.
11. Pillebout E, Weitzman JB, Burtin M, Martino C, Federici P, Yaniv M, et al. JunD protects against chronic kidney disease by regulating paracrine mitogens. J Clin Invest 2003; 112:843-852.
12. Gross ML, Adamczak M, Rabe T, Harbi NA, Krtil J, Koch A, et al. Beneficial effects of estrogens on indices of renal damage in uninephrectomized SHRsp rats. J Am Soc Nephrol 2004; 15:348-358.
13. Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML. The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol 2006; 121:144-158.
14. Shibata S, Nagase M, Yoshida S, Kawarazaki W, Kurihara H, Tanaka H, et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med 2008; 14:1370-1376.
15. Kenyon C. The plasticity of aging: insights from long-lived mutants. Cell 2005; 120:449-460.
16. Tapp DC, Wortham WG, Addison JF, Hammonds DN, Barnes JL, Venkatachalam MA. Food restriction retards body growth and prevents end-stage renal pathology in remnant kidneys of rats regardless of protein intake. Lab Invest 1989; 60:184-195.
17. Kobayashi S, Venkatachalam MA. Differential effects of calorie restriction on glomeruli and tubules of the remnant kidney. Kidney Int 1992; 42:710-717.
18. Le Menuet D, Isnard R, Bichara M, Viengchareun S, Muffat-Joly M, Walker F, et al. Alteration of cardiac and renal functions in transgenic mice overexpressing human mineralocorticoid receptor. J Biol Chem 2001; 276:38911-38920.
19. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 2001; 345:925-926.
20. Kawarazaki H, Ando K, Shibata S, Muraoka K, Fujita M, Kawarasaki C, Fujita T. Mineralocorticoid receptor: Rac1 activation and oxidative stress play major roles in salt-induced hypertension and kidney injury in prepubertal rats. J Hypertens 2012; 30:1977-1985.
21. Shibata S, Mu S, Kawarazaki H, Muraoka K, Ishizawa K, Yoshida S, et al. Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway. J Clin Invest 2011; 121:3233-3243.
22. Lea WB, Kwak ES, Luther JM, Fowler SM, Wang Z, Ma J, et al. Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int 2009; 75:936-944.
23. Kimura G, Dohi Y, Fukuda M. Salt sensitivity and circadian rhythm of blood pressure: the keys to connect CKD with cardiovascular events. Hypertens Res 2010; 33:515-520.